A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Public ClinicalTrials.gov record NCT00728949. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy
Study identification
- NCT ID
- NCT00728949
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 93 participants
Conditions and interventions
Conditions
Interventions
- IMC-A12 (cixutumumab) Biological
- tamoxifen Drug
- Anastrozole Drug
- Letrozole Drug
- Exemestane Drug
- Fulvestrant Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2008
- Primary completion
- Feb 29, 2012
- Completion
- Jan 31, 2015
- Last update posted
- Jun 5, 2018
2008 – 2015
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ImClone Investigational Site | Scottsdale | Arizona | 85259 | — |
| ImClone Investigational Site | Chicago | Illinois | 60611 | — |
| ImClone Investigational Site | Westwood | Kansas | 66205 | — |
| ImClone Investigational Site | Rochester | Minnesota | 55905-0002 | — |
| ImClone Investigational Site | Lebanon | New Hampshire | 03756 | — |
| ImClone Investigational Site | New York | New York | 10021 | — |
| ImClone Investigational Site | The Bronx | New York | 10461 | — |
| ImClone Investigational Site | Columbus | Ohio | 43210 | — |
| ImClone Investigational Site | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00728949, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 5, 2018 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00728949 live on ClinicalTrials.gov.